RxDoctor Payments DataLook up a doctor →

Laura Tanner, MD

Dermatology · Wilmington, NCNPI 1053400499

Payments from drug & device makers

$54,477in general payments, 2019–2025

Across 1,043 payments — averaging $52.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$37K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Sun Pharmaceutical Industries Inc.$2K
  • Novartis$2K
  • Johnson & Johnson$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • plus $7K from 31 others

What the payments were for

  • Consulting fees$2,2584%
  • Speaking & faculty fees$23,80044%
  • Travel & lodging$7,65214%
  • Food & beverage$20,07137%
  • Education$6961%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,477 in reported general payments places this provider in the 90th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$262,365
Medicare patients
1,237
Services billed
3,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HumiraAdalimumab13$162,525
OtezlaApremilast24$116,967
Dupixent SyringeDupilumab11$41,164
Fluorouracil94$6,333
Pimecrolimus14$6,267
Tacrolimus39$4,113
Metronidazole40$2,555
Clobetasol Propionate58$2,055
Fluocinonide40$1,794
Ketoconazole58$1,243
Acitretin15$1,168
Doxycycline Hyclate56$1,158
Terbinafine Hcl56$1,029
Betamethasone Dipropionate12$615
Clindamycin Phosphate13$557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira$37,152$162,52513 claims
AmgenOtezla$273$116,96724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →